The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy
Open accessAbstract
BACKGROUND: Diabetic nephropathy is the leading cause of end-stage renal disease in developed countries. We evaluated the renoprotective effects of dual blockade of the renin-angiotensin-aldosterone system by adding treatment with aliskiren, an oral direct renin inhibitor, to treatment with the maximal recommended dose of losartan (100 mg daily) and optimal antihypertensive therapy in patients who had hypertension and type 2 diabetes with nephropathy. METHODS: We enrolled 599 patients in this multinational, randomized, double-blind study. After a 3-month, open-label, run-in period during which patients received 100 mg of losartan daily, patients were randomly assigned to receive 6 months of treatment with aliskiren (150 mg daily for 3 months, followed by an increase in dosage to 300 mg daily for another 3 months) or placebo, in addition to losartan. The primary outcome was a reduction in the ratio of albumin to creatinine, as measured in an early-morning urine sample, at 6 months. RESULTS: The baseline characteristics of the two groups were similar. Treatment with 300 mg of aliskiren daily, as compared with placebo, reduced the mean urinary albumin-to-creatinine ratio by 20% (95% confidence interval, 9 to 30; P<0.001), with a reduction of 50% or more in 24.7% of the patients who received aliskiren as compared with 12.5% of those who received placebo (P<0.001). A small difference in blood pressure was seen between the treatment groups by the end of the study period (systolic, 2 mm Hg lower [P=0.07] and diastolic, 1 mm Hg lower [P=0.08] in the aliskiren group). The total numbers of adverse and serious adverse events were similar in the groups. CONCLUSIONS: Aliskiren may have renoprotective effects that are independent of its blood-pressure-lowering effect in patients with hypertension, type 2 diabetes, and nephropathy who are receiving the recommended renoprotective treatment. (ClinicalTrials.gov number, NCT00097955 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Self-citationBrenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Self-citationThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Self-citationMultifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Self-citationTelmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
Self-citation[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving, H., Lehnert, H., Brøchner‐Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · PubMed · Cited by 2,535
Self-citationNguyen, G., Delarue, F., Burcklé, C., Bouzhir-Sima, L., Giller, T., & Sraer, J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14276 · Cited by 1,276
Nguyen, G., Delarue, F., Burcklé, C., Bouzhir, L., Giller, T., & Sraer, J.-D. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214276 · Cited by 1,137
Mogensen, C. E., Neldam, S., Tikkanen, I., Oren, S., Viskoper, R., Watts, R. W., & Cooper, M. E. (2000) · BMJ · doi:10.1136/bmj.321.7274.1440 · Cited by 1,037
de Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00653.x · Cited by 975
Self-citationParving, H.-H., Smidt, U., Andersen, A., & Svendsen, P. (1983) · The Lancet · doi:10.1016/s0140-6736(83)92462-5 · Cited by 867
Self-citationSerum kreatininbestimmung ohne enteiweissen
Bartels, H., Böhmer, M., & Heierli, C. (1972) · Clinica Chimica Acta · doi:10.1016/0009-8981(72)90432-9 · Cited by 804
Glomerular hemodynamics in experimental diabetes mellitus
Hostetter, T. H., Troy, J. L., & Brenner, B. M. (1981) · Kidney International · doi:10.1038/ki.1981.33 · Cited by 790
de Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Circulation · doi:10.1161/01.cir.0000139860.33974.28 · Cited by 750
Self-citationIbsen, H., Olsen, M. H., Wachtell, K., Borch-Johnsen, K., Lindholm, L. H., Mogensen, C. E., Dahlöf, B., Devereux, R. B., de Faire, U., Fyhrquist, F., et al. (2005) · Hypertension · doi:10.1161/01.hyp.0000154082.72286.2a · Cited by 562
Gradman, A. H., Schmieder, R. E., Lins, R. L., Nussberger, J., Chiang, Y., & Bedigian, M. P. (2005) · Circulation · doi:10.1161/01.cir.0000156466.02908.ed · Cited by 521
Selective Aldosterone Blockade with Eplerenone Reduces Albuminuria in Patients with Type 2 Diabetes
Epstein, M., Williams, G. H., Weinberger, M., Lewin, A., Krause, S., Mukherjee, R., Patni, R., & Beckerman, B. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00240106 · Cited by 459
Oparil, S., Yarows, S. A., Patel, S., Fang, H., Zhang, J., & Satlin, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61124-6 · Cited by 444
Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population.
Rohlfing, C. L., Little, R. R., Wiedmeyer, H. M., England, J. D., Madsen, R., Harris, M. I., Flegal, K. M., Eberhardt, M. S., & Goldstein, D. E. (2000) · Diabetes Care · doi:10.2337/diacare.23.2.187 · Cited by 370
Increased Plasma Inactive Renin in Diabetes Mellitus: A Marker of Microvascular Complications
Luetscher, J. A., Kraemer, F. B., Wilson, D. M., Schwartz, H. C., & Bryer-Ash, M. (1985) · New England Journal of Medicine · doi:10.1056/nejm198505303122202 · Cited by 335
Renal Dysfunction Complicating the Treatment of Hypertension
Palmer, B. F. (2002) · New England Journal of Medicine · doi:10.1056/nejmra020676 · Cited by 326
Staessen, J. A., Li, Y., & Richart, T. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69442-7 · Cited by 284
Beneficial impact of spironolactone in diabetic nephropathy
Schjoedt, K. J., Rossing, K., Juhl, T. R., Boomsma, F., Rossing, P., Tarnow, L., & Parving, H.-H. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00756.x · Cited by 239
Self-citationR., L., D., K., A., C., N., T., H., H., P., Z., N., P., D., C., & R., G. (2002) · Diabetologia · doi:10.1007/s00125-002-0946-y · Cited by 228
Rossing, K., Schjoedt, K. J., Jensen, B. R., Boomsma, F., & Parving, H.-H. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00511.x · Cited by 225
Self-citationUresin, Y., Taylor, A. A., Kilo, C., Tschöpe, D., Santonastaso, M., Ibram, G., Fang, H., & Satlin, A. (2007) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2007.028 · Cited by 210
Rossing, P., Hommel, E., Smidt, U. M., & Parving, H. H. (1994) · Diabetologia · doi:10.1007/s001250050140 · Cited by 192
Self-citationKelly, D. J., Zhang, Y., Moe, G., Naik, G., & Gilbert, R. E. (2007) · Diabetologia · doi:10.1007/s00125-007-0795-9 · Cited by 167
Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus
Hollenberg, N. K., Parving, H., Viberti, G. C., Remuzzi, G., Ritter, S., Zelenkofske, S. L., Kandra, A., Daley, W. L., & Rocha, R. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e328277596e · Cited by 144
Self-citationGlomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus
Hollenberg, N. K., Price, D. A., Fisher, N. D. L., Lansang, M. C., Perkins, B. A., Gordon, M. S., Williams, G. H., & Laffel, L. M. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00701.x · Cited by 119
Self-citationBakris, G. L., Ruilope, L. M., Locatelli, F., Ptaszynska, A., Pieske, B. M., de Champlain, J., Weber, M. A., & Raz, I. (2007) · Kidney International · doi:10.1038/sj.ki.5002455 · Cited by 103
Nguyen, A.-N. T., Wallace, D. P., & Blanco, G. V. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006010086 · Cited by 91
Trevisan, R., & Tiengo, A. (1995) · American Journal of Hypertension · doi:10.1016/0895-7061(95)00162-i · Cited by 83
Role for TGF-β in Cyclosporine-Induced Modulation of Renal Epithelial Barrier Function
Feldman, G., Kiely, B., Martín-Martín, N., Ryan, G., McMorrow, T., & Ryan, M. P. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006050527 · Cited by 46
Rossing, K. (2007) · PubMed · Cited by 15
Is there a pharmacologic basis for combination renin axis blockade?
Hollenberg, N. K. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00773.x · Cited by 10
Self-citation
Cited by
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Standards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
Metadata
- Authors
- Parving, H.-H., Persson, F., Lewis, J. B., Lewis, E. J., & Hollenberg, N. K.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-06-05
- Volume
- 358
- Issue
- 23
- Pages
- 2433-2446
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2145632481
- Cited by
- 1,098
- References
- 38
- FWCI
- 130.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.